The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

End-of-Year Report showcases significant changes in the tax landscape, indicating additional complexity in 2025KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:VERX) (“Vertex” or the ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary ...

Nowhere are valuations as extended as in the technology sector, particularly among subscription software stocks. Vertex (NASDAQ:VERX), in particular, has seen its share price double over the past ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.

Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...

The relationship between artificial intelligence (AI) and automobiles has been evolving for decades, transitioning from basic ...

Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...